探讨缬沙坦和阿托伐他汀治疗高血压病合并持续性房颤的疗效  

Explore the Curative Effect about Valsartan and Atorvastatin to Treat Hypertention with Persistent Atrial Fibrillation

作　　者：潘冰冰[1] 

机构地区：[1]广西柳州市人民医院,广西柳州545006

出　　处：《中国医药指南》2014年第29期14-15,共2页Guide of China Medicine

摘　　要：目的探讨缬沙坦和阿托伐他汀治疗高血压病合并持续性房颤的疗效。方法选取来我院的高血压病合并持续性房颤患者40例,随机分为两组,每组20例,为实验组和对照组。对照组给予常规的抗凝治疗,服用阿托伐他汀同时服用硝苯地平缓释片;实验组则在对照组的基础上服用缬沙坦治疗。观察两组患者的血压变化、hs-CRP、LAD以及LVMI。结果两组患者治疗前血压无明显差异(P>0.05),治疗后两组患者血压觉得到明显改善,但实验组治疗效果与对照组相比,治疗效果更加良好(P<0.05)。两组患者治疗前hs-CRP、LAD以及LVMI均无显著差异(P>0.05),治疗后,实验组治疗效果明显优于对照组(P<0.05)。结论缬沙坦和阿托伐他汀联合治疗高血压病合并持续性房颤效果明显较之单独使用一种药物效果好,值得临床使用及进一步探讨。Objective To explore the curative effect about valsartan and atorvastatin to treat hypertention with persistent atrial fibrillation. Methods Choose 40 patients with hypertention and persistent atrial fibrillation who came to our hospital last year, randomly dividing into two groups, the experimental group and the control group. The control group was treated with atorvastatin and nifedipine zyban, following with anticoagulation therapy. The experimental group with the control groups the same, besides the valsartan taken. Then, observe the changes of two groups of patients with blood pressure, hs-CRP, LAD and LVMI. Results There is no difference in blood pressure between the two groups of patients before treatment, but the treatment effect of the experimental group is better than the control posttreatment. And there is also no difference in hs-CRP, LAD and LVMI between the two groups of patients before treatment, but the treatment effect of the experimental group is also better than the control posttreatment. Conclusion The combination of valsartan and atorvastatin is better than the use of only one kind of drugs above, and it is worthy to apply and further discuss in clinical.

关 键 词：高血压 持续性房颤 缬沙坦 阿托伐他汀 

分 类 号：R544.1[医药卫生—心血管疾病]